METEOR Trial: Study design

1
METEOR Trial Study design
Measuring Effects on intima-media Thickness an
Evaluation Of Rosuvastatin Trial
N 984 with subclinical atherosclerosis, LDL-C
120 to lt190 mg/dL (age only CHD risk factor)
or LDL-C 120 to lt160 mg/dL (2 CHD risk factors
but lt10 FRS), HDL-C 60 mg/dL, TG lt500 mg/dL
Rosuvastatin 40 mg n 702
Placebon 282
Primary endpoint Rate of change in maximum CIMT
for 12 carotid sites
Follow-up 2 years
FRS Framingham risk scoreMaximum carotid
intima-media thickness (CIMT) 1.2 mm to lt3.5 mm
Crouse JR III et al. JAMA. 20072971344-53.
2
Changes in CIMT with rosuvastatin vs placebo
METEOR Trial
0.04
0.03
0.02
0.01
? Maximum CIMT (mm)
0
-0.01
-0.02
-0.03
-0.04
0
6
12
18
24
Months
Placebo Rosuvastatin 40 mg
Shading indicates 95 CI
Crouse JR III et al. JAMA. 20072971344-53.
3
METEOR Trial highlights

• Objective
• Does treatment with rosuvastatin 40 mg slow
  progression or induce regression of CIMT in
  low-risk individuals with mild to moderate
  atherosclerosis?
• Main results
• A significant reduction in the rate of maximal
  CIMT progression was observed with rosuvastatin
  vs placebo
• Significant CIMT regression was not observed in
  either group
• Clinical implications
• Even in low-risk, middle-aged individuals,
  cholesterol management with rosuvastatin
  treatment slowed the progression of CIMT over 2
  years

Crouse JR III et al. JAMA. 20072971344-53.